446 related articles for article (PubMed ID: 29059438)
1. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
2. Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.
Sanmartín E; Muñoz L; Piqueras M; Sirerol JA; Berlanga P; Cañete A; Castel V; Font de Mora J
Clin Cancer Res; 2017 Nov; 23(22):6875-6887. PubMed ID: 28830922
[No Abstract] [Full Text] [Related]
3. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
4. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
7. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Williamson CT; Muzik H; Turhan AG; Zamò A; O'Connor MJ; Bebb DG; Lees-Miller SP
Mol Cancer Ther; 2010 Feb; 9(2):347-57. PubMed ID: 20124459
[TBL] [Abstract][Full Text] [Related]
8. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M; Hernández-Sánchez M; Alonso-Pérez V; Rodríguez-Vicente AE; García-Tuñón I; Martín-Izquierdo M; Hernández-Sánchez JM; Herrero AB; Bastida JM; San Segundo L; Gruber M; García JL; Yin S; Ten Hacken E; Benito R; Ordóñez JL; Wu CJ; Hernández-Rivas JM
Leukemia; 2020 Jun; 34(6):1599-1612. PubMed ID: 31974435
[TBL] [Abstract][Full Text] [Related]
10. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
11. Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma.
Parikh RA; White JS; Huang X; Schoppy DW; Baysal BE; Baskaran R; Bakkenist CJ; Saunders WS; Hsu LC; Romkes M; Gollin SM
Genes Chromosomes Cancer; 2007 Aug; 46(8):761-75. PubMed ID: 17492757
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
13. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
14. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
15. ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors.
Parvin S; Akter J; Takenobu H; Katai Y; Satoh S; Okada R; Haruta M; Mukae K; Wada T; Ohira M; Ando K; Kamijo T
BMC Cancer; 2023 Apr; 23(1):313. PubMed ID: 37020276
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP
EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035
[TBL] [Abstract][Full Text] [Related]
17.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
18. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
19. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
